Metformin Still Best as First Type 2 Diabetes Treatment
American College of Physicians updated diabetes guidelines, said second drug can be added
By Randy Dotinga
Tuesday, January 3, 2017
MONDAY, Jan. 2, 2017 (HealthDay News) -- Newly updated guidelines reaffirm that metformin is the first-line drug for people with type 2 diabetes, and that several other medications -- including newer ones -- can be added if needed.
The recommendations come from the American College of Physicians (ACP). The American Academy of Family Physicians endorsed the new guidelines. The ACP updated the guidelines because of new research into diabetes drugs, and the U.S. Food and Drug Administration approval of new diabetes drugs.
"Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications," ACP president Dr. Nitin Damle said in a college news release.
"The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has the added benefit of being associated with weight loss," Damle said.
The ACP recommends that if a patient needs to take a second drug by mouth to lower blood sugar levels, physicians should look at adding a sulfonylurea, thiazolidinedione, SGLT-2 inhibitor, or a DPP-4 inhibitor.
Examples of sulfonylurea drugs include glyburide (Diabeta, Glucovance, Micronase), glimepiride, glipizide (Glucotrol) and tolbutamide. Thiazolidinedione drugs include pioglitazone (Actos) and rosiglitazone (Avandia).
SGLT-2 inhibitors include canagliflozin (Invokana), empagliflozin (Jardiance) and dapagliflozin (Farxiga). DPP-4 inhibitors include sitagliptin (Janumet, Januvia) or linagliptin (Jentadueto, Tradjenta). Brand names for metformin include Glumetza, Glucophage, and Fortamet.
"Adding a second medication to metformin may provide additional benefits," Damle said.
"However, the increased cost may not always support the added benefit, particularly for the more expensive, newer medications. ACP recommends that clinicians and patients discuss the benefits, adverse effects, and costs of additional medications," he added.
An estimated 29 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention.
The guidelines are published in the Jan. 3 issue of the Annals of Internal Medicine.
SOURCE: American College of Physicians, news release, Jan. 2, 2017
Copyright (c) 2017 HealthDay. All rights reserved.
News stories are provided by HealthDay and do not reflect the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, the U.S. Department of Health and Human Services, or federal policy.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||